1. Volume 148, Issue 7, Pages 1311-1319.e6 (June 2015)
Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial 
Daniel A. Leffler, Ciaran P. Kelly, Peter H.R. Green, Richard N. Fedorak, Anthony DiMarino, Wendy Perrow, Henrik Rasmussen, Chao Wang, Premysl Bercik, Natalie M. Bachir, Joseph A. Murray 
Gastroenterology 
Volume 148, Issue 7, Pages e6 (June 2015)
DOI: /j.gastro
Copyright © 2015 AGA Institute Terms and Conditions

2. Figure 1
Primary end point: average on-treatment scores on the CeD-GSRS. The 0.5-mg larazotide acetate dose met the primary end point.
Gastroenterology  , e6DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

3. Figure 2
Larazotide acetate 0.5 mg 3 times per day reduced the average on-treatment weekly number of CeD PRO symptomatic days. Symptomatic days defined a priori as a day with a mean score of ≥3 on either the abdominal symptom or diarrhea/loose stool domains.
Gastroenterology  , e6DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

4. Supplementary Figure 1 Study design and patient disposition.
Gastroenterology  , e6DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

5. Supplementary Figure 2
Tight junction structure and mechanism of action of larazotide acetate. Larazotide acetate is a TJ regulator octapeptide inhibitor of Vibrio cholera zonula occludens (ZO) toxin. TJs comprise more than 50 proteins, including the transmembrane proteins occluding claudin, junctional adhesion molecule (JAM), and cytoplasmic scaffolding proteins ZO-1, ZO-2, and ZO-3. Larazotide acetate inhibits the cytoskeletal rearrangement and ZO-1 redistribution caused by gliadin in epithelial cells regulates actin rearrangement and stabilizes TJ in vitro in response to various stimuli, including inflammatory cytokines, bacterial products, and gliadin. In addition, larazotide acetate inhibits transepithelial gliadin transport in vitro and decreases intestinal permeability and preserves barrier function in vitro and in vivo.
Reprinted with permission from Martinez et al. Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome. Gut Liver 2012;6:305–315. © Korean Association of Medical Journal Editors.
Gastroenterology  , e6DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

6. Supplementary Figure 3
No increase or worsening of serum antibody levels.
Gastroenterology  , e6DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions